 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- 1% capsaicin topical liquid (CGS-200-1) / Vizuri Health Sciences, 5% capsaicin topical liquid (CGS-200-5) / Vizuri Health Sciences
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin) (B206) - Oct 7, 2019 - Abstract #ACRARHP2019ACR_3808;
CGS-200-5 was well-tolerated and efficacious following application to both knees for 60 minutes on 4 consecutive days. Due to the significant efficacy and good safety and tolerability observed in this study, further clinical development of CGS-200-5 is warranted.
- ||| 5% capsaicin topical liquid (CGS-200-5) / Astellas
Trial completion: A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control (clinicaltrials.gov) - Jun 6, 2019
P2, N=122, Completed, Sponsor: Vizuri Health Sciences LLC
Due to the significant efficacy and good safety and tolerability observed in this study, further clinical development of CGS-200-5 is warranted. Active, not recruiting --> Completed
- | 5% capsaicin topical liquid (CGS-200-5) / Astellas
Enrollment closed: A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control (clinicaltrials.gov) - Oct 1, 2018
P2, N=122, Active, not recruiting, Sponsor: Vizuri Health Sciences LLC
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | 5% capsaicin topical liquid (CGS-200-5) / Astellas
New P2 trial: A Phase 2 Clinical Trial Examining the Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5 and Vehicle Control (clinicaltrials.gov) - May 18, 2018
P2, N=120, Not yet recruiting, Sponsor: Vizuri Health Sciences LLC